
Last updated: 2026-09-16 10:31:40. Prices reflect the latest pre-market trading data. Stock price data is sourced from Massive.
InflaRx N.V (IFRX) operates in the -- sector and is listed on NASDAQ. The stock is currently priced at $2.02, with a market capitalisation of $312.42M and a P/E ratio of --. Over the past 52 weeks, its price has ranged from $0.80 to $2.95. This page covers its latest market performance, valuation, price trends and company information.
$312.42M | |
$2.12 | |
$53.10 | |
$0.71 | |
$2.12 | |
560.73K | |
1.05M | |
-- | |
$2.95 | |
$0.80 | |
-- | |
-- |
InflaRx N.V (IFRX) is trading at $2.13 in pre-market trading as of 2026-09-15 23:31:00, up 0.24% ($0.00) from the previous close of $2.12
Pre-market trading shows how investors are pricing IFRX before the regular session opens. The current pre-market price is near the previous close, indicating positive early trading sentiment.
Over the past seven days, InflaRx N.V (IFRX) moved from $2.22 to $2.02, representing a decline of 8.96% ($0.20).
The stock traded between $1.98 and $2.38 during the period. The latest price is near the lower end of the 7-day range, indicating strong downward.
The average daily volume was 519.37 thousand shares, down versus the previous seven-day period, indicating lower trading activity.
Position in Range: 56.9%
IFRX is currently trading at $2.02, placing it 56.9% of the way from its 52-week low of $0.80 to its 52-week high of $2.95. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
InflaRx NV is a biopharmaceutical company applying proprietary technologies to discover, develop and commercialize potent and specific inhibitors of the complement activation factor known as C5a and its receptor C5aR. With its therapeutic product candidates, vilobelimab and izicopan, the company targets C5a and its receptor C5aR to selectively inhibit the powerful inflammatory response observed in a wide variety of autoimmune and other inflammatory diseases elicited through C5a/C5aR activation. Its product candidate, GOHIBIC (vilobelimab), is a novel intravenously delivered anti-C5a monoclonal antibody that selectively binds to free C5a and has demonstrated disease-modifying clinical activity and tolerability in multiple clinical settings.
| Employees | 65 |
| Exchange | NASDAQ |
| Company Website |
Eligible investors can buy real shares of InflaRx N.V (IFRX) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.